AAN 2022 poster: Associations between steroid treatment and clinical outcomes among non-ambulatory patients with Duchenne muscular dystrophy (DMD)
This poster, presented at the 2022 AAN Annual Meeting in Seattle, USA, presents the results of a comparison of corticosteroid treatments in non-ambulatory patients with DMD
Find out about the study design and baseline characteristics of 86 non-ambulatory patients with DMD who were identified from the PRO-DMD-01 study for analysis
Read more on the clinical findings associated with treatment with different corticosteroids, or no corticosteroids, measured by pulmonary, cardiac, and functional outcomes
Deflazacort is a corticosteroid indicated for the treatment of DMD in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.